Published in Blood Weekly, April 17th, 2003
"The objective of this prospective study was to determine the prevalence of hyperlipidemia in our pediatric renal transplant patients and to treat those with persistently elevated cholesterol and/or low-density lipoprotein (LDL) levels. All patients with a functioning renal allograft for greater than 6 months were studied (n=18).
"Patients with cholesterol and/or LDL levels greater than the 95th percentile (n=9) were commenced on an HMG-CoA reductase inhibitor Atorvastatin and monitoring was performed for efficacy and adverse effects," researchers in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.